In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:<ul><li>Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC</li><li>Long-term safety observations for crizotinib and entrectinib </li><li>CNS activity of entrectinib and repotrectinib in patients with brain metastases</li><li>Repotrectinib activity in ROS1-TKI resistance mutations   </li></ul>Program faculty:Jessica J. Lin, MD Attending Physician Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, MassachusettsAlice T. Shaw, MD, PhD Chief, Strategic Partnerships Attending Physician, Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, MassachusettsResources: To download the slides associated with this podcast discussion, please visit the <a href="https://bit.ly/3T9IVFf" target="_blank">program page</a>.

Clinical Care Options

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

cco oncology podcast

CCO Oncology Podcast

Audio podcast with highlights from a live webinar covering available clinical data and approved treatments for ROS1-altered TKI-naive advanced non-small-cell lung cancer (NSCLC). Listen to the experts review and discuss their perspectives and summarize clinical data in support of guideline-recommended first-line treatment approaches.

Episode Summary

Clips